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Recent evidence indicates that cyclin-dependent kinases (CDKs,
cdks) may be inappropriately activated in several neurodegenera-
tive conditions. Here, we report that cdk5 expression and activity
are elevated after administration of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), a toxin that damages the nigrostriatal
dopaminergic pathway. Supporting the pathogenic significance of
the cdk5 alterations are the findings that the general cdk inhibitor,
flavopiridol, or expression of dominant-negative cdk5, and to
a lesser extent dominant-negative cdk2, attenuates the loss of
dopaminergic neurons caused by MPTP. In addition, CDK inhibition
strategies attenuate MPTP-induced hypolocomotion and markers
of striatal function independent of striatal dopamine. We propose
that cdk5 is a key regulator in the degeneration of dopaminergic
neurons in Parkinson’s disease.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine  neurodegeneration
Parkinson’s disease (PD) is a neurodegenerative disordercharacterized by disabling motor abnormalities, including
tremor, muscle rigidity, paucity of voluntary movements, and
postural instability (1). In several mammalian species, 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces most of
the biochemical and pathological alterations seen in PD, includ-
ing the loss of dopaminergic neurons of the substantia nigra pars
compacta (SNc) (1). Current treatment strategies for PD consist
primarily of dopamine replacement therapy with levodopa or
dopamine agonists (1). Although effective in the early stages of
the disease, chronic dopamine replacement therapy can cause
debilitating side effects. Accordingly, concerted research efforts
have been focused on developing neuroprotective strategies that
will halt or slow the progression of PD.
Recent evidence implicates cyclin-dependent kinases (CDKs)
in the pathogenesis of several neurodegenerative disorders.
CDKs are serinethreonine kinases best characterized for their
role in cell cycle progression. To be active, CDKs require binding
to specific regulatory partners such as cyclins (2). Up-regulation
of a variety of cell cycle-related CDKs andor cyclins has been
reported in a number of in vitro neuronal death paradigms (3–8).
The importance of such observations is substantiated by reports
that inappropriate activation of cell cycle-related pathways has
been correlated with the pathogenesis of stroke (9, 10) and
Alzheimer’s disease (11). However, the identity and functional
requirement of individual CDK members in neurodegeneration
remain to be elucidated.
In contrast to the mitotic CDKs, cdk5 activity is predomi-
nantly, although not exclusively, associated with postmitotic
neurons (12). cdk5 activation requires association with its reg-
ulatory partner, p35 (13) or p39 (14). The p35cdk5 complex is
required for proper development of the central nervous system
(15, 16), process outgrowth (17), axonal migration (18, 19),
cortical lamination (16, 20), cell adhesion (20), axonal transport
(21), and synaptic activity (22). Just as with cell cycle-related
CDKs, deregulated cdk5 activity may play a role in neurode-
generation. For example, proteolytic cleavage of the cdk5 acti-
vator p35 to the more stable p25 form has been reported in brains
of patients with Alzheimer’s disease (23). In addition, overex-
pression of p25cdk5 complex has been shown to induce neu-
ronal death in culture (24) and cytoskeletal abnormalities in
transgenic mice (24). Deregulation of cdk5 has also been doc-
umented in a mutant superoxide dismutase (SOD) animal model
of amyotrophic lateral sclerosis (25) and in a murine model of
Niemann–Pick type C disease (26). With regards to PD, previous
reports have suggested that cdk5 is elevated in dopamine neu-
rons of human postmortem PD brains (27, 28). In addition,
ectopic expression of cdk5 as well as cell cycle-related CDKs has
been shown to occur in neonatal rat dopamine neurons under-
going programmed cell death in vivo (29–31).
From these observations, two major questions arise: (i) what
is the functional relevance of CDKs in adult models of neuro-
degeneration, and (ii) which CDKs participate in neuronal loss
in vivo. To address these questions, we examined the functional
consequences of CDK inhibition in an in vivo mouse model of
PD. We present evidence for the importance of cdk5, and to a
lesser extent cdk2, in dopaminergic neuron loss induced by
MPTP, and we suggest that cdk5 plays a key role in the
pathogenesis of PD.
Materials and Methods
Animals. Eight-week-old male C57BL6 mice (22–28 g; Charles
River Laboratories) were used for all experiments. All animal
experiments conformed to the guidelines set forth by the Ca-
nadian Council for the Use and Care of Animals in Research
(CCAC) and the Canadian Institutes for Health Research
(CIHR) and with approval from the University of Ottawa
Animal Care Committee.
MPTP Administration. Mice received one i.p. injection of
MPTPHCl per day (25 mg of free base per kg of body weight
per day; Sigma) for 5 consecutive days (32); control mice
received an equivalent volume of 0.9% saline. Brains were
extracted at indicated times and either perfused for immuno-
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histochemical analyses or quickly removed and dissected for
biochemical analyses.
Administration of the Pharmacological Inhibitor. Cannulae attached
to osmotic minipumps (Alzet model 1007D) were implanted into
the right lateral ventricle as previously described (33). Pumps
contained 200 l of f lavopiridol [300 M in artificial cerebrov-
entricular fluid (aCSF)] or vehicle (aCSF). Cannulae with
attached pumps were stereotaxically implanted 1 day before the
initiation of MPTP treatment (as described above). Brains were
extracted 14 days after MPTP treatment for immunohistochem-
ical detection of dopamine neuron loss.
Intrastriatal Administration of Adenoviruses. The adenoviruses
expressing the dominant-negative (DN) form of various cdks
were engineered by using a Cre-lox adenoviral construction
system (CDK constructs were generously provided by E. Harlow,
Harvard Medical School, Boston). We and others have previ-
ously shown that adenoviruses can target the SNc from the
striatum by retrograde transport (34). Each adenovirus was
injected directly into the striatum of animals 7 days before
initiation of MPTP treatment (as described above). A lacZ-
containing construct was used as a control for all adenovirus
experiments. A single unilateral injection of each virus (2 l, 1
107 particles per l) expressing FLAG-tagged DN forms of cdk5
(DN cdk5), cdk2 (DN cdk2), cdk4 (DN cdk4), and cdk6 (DN
cdk6) was delivered to the right striatum (0.5 mm rostral, 2.2 mm
right of bregma, and 3.4 mm below the skull surface). Each
adenovirus injection was given at a constant rate (0.5 lmin) by
using a syringe pump system. Brains were extracted for immu-
nohistochemistry and Western blot analysis 14 days after the first
MPTP treatment.
Immunohistochemistry. Mice were perfused transcardially and
brains were fixed in paraformaldehyde and cryoprotected as
previously described (33). Serial coronal sections (14-m thick-
ness) of the ventral midbrain and the striatum were collected
either on slides or free-floating (in 0.01 M PBS0.02% sodium
azide). Sections were then incubated in primary antibody [to
tyrosine hydroxylase (TH), 1:10,000, ImmunoStar; phospho-
(AT8), 1:2,000, Innogenetics; cdk5, C-8, 1:1,000, Santa Cruz
Biotechnology; and FLAG, 1:1,000, Sigma; all dilutions made in
0.3% Triton X-1000.01 M PBS] for 48 h at 4°C. Sections were
then incubated with biotinylated secondary antibody and
streptavidin horseradish peroxidase-conjugated tertiary anti-
body and visualized by using a 3,3-diaminobenzidineglucose
oxidase reaction as previously described (35). Alternatively,
sections were visualized after incubation with CY3-conjugated
secondary antibody (1:200, Jackson ImmunoResearch). To ex-
amine the colocalization of cdk5 with TH, a double-labeling
immunofluorescence approach was used. After incubation with
the specific primary antibody at 4°C, immunolabeling was visu-
alized by using either CY3-conjugated anti-mouse IgG (1:200,
Jackson ImmunoResearch) or biotinylated secondary antibody
(1:200, Jackson ImmunoResearch) followed by streptavidin
FITC antibody (1:200, Amersham Biosciences).
Quantification of Dopamine Neuron Loss. Loss of dopamine neurons
was assessed by immunohistochemical analysis of TH-positive
neurons in the anatomical region of the SNc corresponding to
bregma  3.08 through bregma  3.40 (36). Sections were also
stained with cresyl violet at the level of the medial terminal
nucleus (MTN) as an independent measure of neuronal survival
in the SNc. Total TH-positive neurons were estimated by using
Abercrombie’s correction (37).
For experiments using the gene delivery approach, only
sections in the region containing the MTN were included. The
region of the MTN has been previously shown to contain the
highest level of virus-mediated expression after intrastriatal
infection (34). Neurons ipsilateral and contralateral to the viral
injection were assessed as described above in at least five sections
per animal. The ratio of neurons ipsilateralcontralateral to the
injection was then calculated accordingly.
Western Blot Analysis. Briefly, a 2-mm coronal slab of the mid-
brain region was isolated by using a brain matrix. SNc tissue
extracts were isolated by using a 1-mm-diameter needle to dissect
the SNc area. Total tissue proteins were isolated from a micro-
dissection of the substantia nigra and striatum by using a biopsy
needle. Samples were homogenized in lysate buffer containing
50 mM Hepes at pH 7.5, 150 mM NaCl, 1 mM EDTA, 2.5 mM
EGTA, 1 mM DTT, 10% glycerol, 0.1 mM PMSF, 10 gml
leupeptin, 1 gml aprotinin, 10 mM -glycerophosphate, 1 mM
NaF, and 0.1 mM sodium orthovanadate. Protein concentration
was determined by the Bradford method (Bio-Rad). Thirty
micrograms of protein was analyzed by SDSPAGE as described
previously (5), using antibodies to AT8, retinoblastoma protein
(Rb) phosphorylated on Ser-795 or Ser-805811 (Cell Signal-
ing), and actin (Sigma).
Behavioral Analysis. Behavioral analyses were carried out by using
an open field test approach to measure amphetamine-induced
locomotion in a novel environment, as described previously (33).
HPLC and 1-Methyl-4-phenylpyridinium (MPP) Analyses. Dopamine
and metabolites and MPP were assessed by HPLC analyses as
previously described (32).
cdk Kinase Assay. Tissue from the SNc was homogenized in 0.5 ml
of lysate buffer containing 250 mM NaCl, 5 mM EDTA, 0.1%
Nonidet P-40, 5 mM DTT, 10 mM NaF, 1 gml aprotinin, 1
gml leupeptin, 1 mM PMSF, and 50 mM TrisHCl at pH 7.5
(38). Samples were then centrifuged at 12,000  g, and protein
concentration was determined by the Bradford method. A 50-g
sample of protein from the supernatant was incubated overnight
at 4°C with 1 g of individual cdk antibodies (cdk5, C-8; cdk2,
D-12; cdk4, H-22; and cdk6, C-21). Thirty microliters of staph-
ylococcal protein A-Sepharose (Sigma) was added to the immu-
noprecipitates and samples were incubated for 2 h at 4°C. The
immune complexes were then pelleted at 14,000 g and washed
in kinase buffer containing 20 mM Hepes at pH 7.6, 20 mM
MgCl2, 20 mM -glycerophosphate, 0.1 mM sodium orthovana-
date, 2 mM DTT, and 20 M unlabeled ATP. After washing,
beads were incubated in kinase buffer as described above
containing 2 g of histone H1 or Rb (Cell Signaling) and 1.2 Ci
(1 Ci  37 kBq) of [-32P]ATP per sample in a final volume of
50 l at 30°C for 20 min. Kinase activity was determined by
SDSPAGE and autoradiography.
Results
MPTP Treatment Induces Increase in Expression and Activity of cdk5.
To determine whether cdk5 expression is regulated by MPTP
administration, we assessed cdk5 levels in the SNc of mice
treated with MPTP. We detected increased cdk5 expression
(Fig. 1 A and B) in the SNc, whereas cotreatment with the
general CDK inhibitor flavopiridol did not affect cdk5 induction
(data not shown). This observation is consistent with the idea
that flavopiridol inhibits CDK activity and does not affect
induction of the CDK protein. In addition, colabeling immuno-
fluorescence revealed that cdk5 elevation occurs in dopaminer-
gic neurons of the SNc after MPTP treatment (Fig. 1 C and D).
cdk5TH neurons were increased 5- to 6-fold after MPTP
treatment compared with saline-treated animals (Fig. 1E). To
determine whether the observed increase in cdk5 levels was
associated with elevation in cdk5 kinase activity, we evaluated
the phosphorylation state of  (phospho-, AT8), a substrate of
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cdk5 (39). Immunohistochemical (Fig. 1 F–I) and Western blot
(Fig. 1J) analyses revealed that AT8 was markedly increased in
the SNc after MPTP treatment. Importantly, f lavopiridol ad-
ministration attenuated MPTP-induced phosphorylation of  in
the substantia nigra (Fig. 1I). An increase in cdk5 activity after
MPTP treatment was also substantiated by an in vitro kinase
assay after immunoprecipitation of cdk5 (Fig. 1J). Finally,
increased levels of p25 have been suggested to contribute to
increased cdk5 activity (23). Indeed, we show here that p25 levels
are up-regulated after MPTP treatment (Fig. 1K). These data
indicate that cdk5 activity is increased in the SNc after chronic
MPTP administration. To determine whether activation of
mitotic CDKs occurred in this paradigm, we investigated the
phosphorylation state of Rb on Ser-795 and Ser-805811, known
cdk46 phosphorylation sites. We did not detect any increase in
phosphorylation at these sites after MPTP treatment, by either
Western blot or immunohistochemical analysis, indicating that
Rb is not likely involved in the degeneration process (data not
shown). Consistent with this idea, we could not detect an
increase in cdk4 levels by Western blot analysis (data not shown)
or cdk4 activity by in vitro immunoprecipitation kinase assay
(Fig. 1L). However, cdk2 levels (data not shown) and activity
were detectably increased after MPTP treatment (Fig. 1L).
Inhibition of cdk5 Provides Neuroprotection Against MPTP-Induced
Loss of Dopamine Neurons of the Nigrostriatal Dopamine Pathway. To
determine whether CDK activation was related to dopaminergic
neuron loss after MPTP treatment, we examined the neuropro-
tective effects of the general cdk inhibitor flavopiridol. As shown
in Fig. 2 A–D, f lavopiridol treatment attenuated MPTP-induced
loss of TH-positive neurons in the SNc after chronic MPTP
treatment. Because MPTP may elicit the loss of TH expression
rather than death of the neuron, we used an independent
histological marker (cresyl violet) to assess SNc neuron survival.
(Fig. 2E). Results from the cresyl violet analyses were consistent
with the TH counts. These results indicate that flavopiridol
treatment is effective in protecting dopaminergic neurons from
degeneration caused by MPTP. MPTP-induced dopaminergic
neurotoxicity correlates linearly with the striatal content of
MPTP’s active metabolite, MPP. To determine whether fla-
vopiridol-induced neuroprotective effects were attributable to
alterations in brain MPP accumulation, we measured striatal
and ventral midbrain levels of MPP 90 min after injection of
MPTP. We did not detect any appreciable flavopiridol-induced
alteration in MPP levels after MPTP treatment (Fig. 2F).
Although the above evidence suggests the importance of
CDKs in this MPTP paradigm, it is important to note that
flavopiridol inhibits several enzymes, including cdk2 [IC50 0.17
M, (40)], cdk4 [IC50  0.40 M, (41)], and cdk5 [IC50  0.17
M, (42)]. Therefore, to more fully understand how flavopiridol
is providing its neuroprotective effects, we used a second ap-
proach with DN, kinase-dead mutant forms of individual CDKs.
Adenoviruses expressing FLAG-tagged DN forms of cdk5 (DN
cdk5), cdk2 (DN cdk2), cdk4 (DN cdk4), and cdk6 (DN cdk6) or
a lacZ control were individually injected unilaterally into the
mouse striatum 7 days before the initiation of MPTP treatment
(34). FLAG-tagged viral proteins were detected by both Western
blot analyses and immunohistochemistry (Fig. 3). TH-positive
neurons were analyzed 14 days after chronic MPTP adminis-
tration at the level of the MTN (the level at which virus-mediated
Fig. 1. Increased cdk5 expression and activity in the SNc of MPTP-treated
mice. (A and B) Expression of cdk5 in the SNc of mice treated with saline (A) or
MPTP (14 days) (B). (C and D) Representative photomicrographs illustrating
the coexpression of cdk5 (D) with TH-positive (C) cells. (E) Quantitative anal-
yses of THcdk5 neurons. Each bar represents mean  SEM; * indicates
statistical significance (Student’s t test, P 0.01, n 4). (F–H) Representative
photomicrographs showing AT8 expression in the SNc of mice treated with
saline (F), MPTP (14 days) and vehicle (G), or MPTP and flavopiridol (H). (I)
Quantitative analysis of AT8-positive neurons of the SNc. Each bar represents
the mean  SEM; ** indicates statistical significance (ANOVA, P  0.001, n 
6–8). (J) Western blot analyses (AT8 expression, 50- to 55-kDa species) and in
vitro kinase assay (histone H1 substrate) indicating cdk5 activity in SNc extracts
after saline treatment (lane 1), 12 h after chronic MPTP (lane 2), and 14 days
after chronic MPTP treatment (lane 3). CB, Coomassie blue stain as loading
control. (K) Western blot showing the expression of the cdk5 activator p25
after saline treatment and chronic MPTP treatment at the indicated times. (L)
In vitro immunoprecipitate kinase assay showing activity of cdk2 (with histone
H1 as substrate) and cdk4 (with Rb as substrate) after MPTP treatment for the
indicated times.
Fig. 2. Flavopiridol administration attenuates MPTP-induced degeneration
of nigral dopamine neurons. (A–C) Representative TH immunoreactivity in the
ventral midbrain of animals treated with saline (A), vehicleMPTP (B), or
flavopiridolMPTP (C). (D) Quantitative analyses of TH-positive neurons of the
SNc. (E) Quantitative analyses of cresyl violet staining at the level of the MTN.
Each bar represents the mean  SEM; * denotes significance (ANOVA, P 
0.0.05, n  6–8). (F) MPP measurements, 90 min after a single-dose MPTP
injection into animals treated with either vehicle or flavopiridol (given 24 h
before MPTP treatment). Bar graph represents the levels of MPP recorded by
HPLC analyses (n  4 or 5 per group) in striatum (STR) and SNc.
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expression is highest). As shown in Fig. 3, animals expressing DN
cdk5 showed a greater number of TH-positive neurons in the
ipsilateral virus-injected side compared with the contralateral
control side of the same animal (60% increase vs. 10% in
controls). Mice expressing DN cdk2 also showed some protec-
tion (25% with DN cdk2 vs. 10% with controls), although to a
much lesser extent than DN cdk5-infected brains (Fig. 3). In
contrast, DN cdk4, DN cdk6, or LacZ expression did not protect
SNc neurons from MPTP-induced dopaminergic neuron loss.
Administration of individual viruses alone in the absence of
MPTP treatment did not result in any significant degeneration
of dopamine neurons compared with lacZsaline controls (data
not shown).
CDK Inhibition and Function. To evaluate the functional impact of
CDK inhibition, we carried out behavioral analyses to detect
gross motor activity of mice in an open-field test after amphet-
amine challenge. Locomotor activity was detected by using a
computer-assisted video-tracking system that measures amphet-
amine-induced activity of each animal over a period of 30 min.
Previous work had demonstrated that MPTP administration
reduces amphetamine-induced motor activity (43). As shown in
Fig. 4A, MPTP-injected mice showed significant decrease in
gross activity compared with saline controls. Flavopiridol treat-
ment significantly improved MPTP-induced hypolocomotion to
a level not significantly different from that recorded for saline
controls.
With evidence indicating that CDK inhibition attenuates
MPTP-induced loss of dopaminergic cell bodies (Fig. 2) and
improves an aspect of motor behavior, we next evaluated the
protective effects of CDK inhibition on the integrity of striatal
function. Although PD is characterized predominantly by the
progressive loss of dopamine neurons in the SNc, the main
manifestations of the disorder are thought to be mediated by
striatal dysfunction, a consequence of cell body loss in the SNc
(44). Importantly, neuroprotection did not lead to an improve-
ment in striatal dopamine levels as assessed by HPLC analyses
(Fig. 4B). In addition, there was no significant difference in
dopamine turnover as measured by the ratio of 3,4-dihydroxy-
phenylacetic acid to dopamine in any treatment group (data not
shown). Taken together, these data indicate that although there
was histological preservation of cell bodies in the SNc, striatal
dopamine fibers were functionally impaired with respect to
dopamine content.
Because there appeared to be indications of improved loco-
motor activity without normalized dopamine levels in the stri-
atum, we hypothesized that flavopiridol-mediated neuroprotec-
tion of dopamine neuron cell bodies might indirectly modulate
postsynaptic striatal function. Expression of the immediate early
gene encoding  FosB is dramatically up-regulated in the do-
paminergically denervated striatum after MPTP treatment (45).
FosB up-regulation is associated with neural plasticity during
addiction and with hypersensitization of striatal dopamine re-
ceptors after denervation (46). Accordingly, we surmised that if
the striatal circuitry were normalized with flavopiridol treat-
ment, then delta FosB induction would also be attenuated. The
results indicate that MPTP-induced FosB expression was signif-
Fig. 3. Adenovirus-mediated inhibition of cdk5 provides significant protec-
tion from MPTP-induced degeneration of dopaminergic neurons of the SNc.
(A–C) Representative photomicrographs of TH immunoreactivity in the ven-
tral midbrain (MTN level) of saline-treated mice (A), mice expressing lacZ and
treated with MPTP 14 days earlier (B), and mice expressing DN cdk5 and MPTP
(C). Mice were treated with a single unilateral virus injection into the striatum
as described in Materials and Methods. (G) Quantitation of TH-positive neu-
rons in the SNc for the indicated treatment groups. Values are described as
percent increase in the number of neurons in the ipsilateral (virus-injected) vs.
noninjected contralateral control side. Data are represented as mean  SEM
(n 6 animals per group). * and ** denote significance P 0.05 and P 0.001,
respectively (ANOVA). (Insets) Expression of DN cdk2, -5, and -6 in SNc extracts
by Western blot analyses using an anti-FLAG antibody. (Insets) Lane 1, con-
tralateral control side; lane 2, ipsilateral virus-injected side; and lane 3,
noninjected control animal. LC, loading control (Coomassie blue staining).
(D–F) Immunofluorescence analyses showing the expression of FLAG-tagged
DN proteins in the SNc of animals treated with lacZ (D), DN cdk5 (E), or
DN cdk2 (F).
Fig. 4. Flavopiridol administration reduces behavioral impairments and 
FosB (a marker for postsynaptic changes in the denervated striatum levels)
after MPTP treatment in mice but does not prevent loss of striatal dopamine.
(A) Locomotor activity 14 days after chronic MPTP treatment. Bar graph
represents total activity over a 30-min period immediately after amphetamine
challenge in a novel open-field test. Each bar represents the mean SEM (n
6–8 animals per group); * indicates statistical significance (P0.001, ANOVA).
(B) Striatal dopamine content. The striatum was extracted from mice treated
with either vehicleMPTP (14 days) or flavopiridolMPTP (14 days) and ana-
lyzed for dopamine levels by HPLC. Values are expressed as mean  SEM; *
denotes statistical significance (Student’s t test, P 0.01). (C–E) Expression of
 FosB in the striatum of mice treated with saline (C), vehicle and MPTP (14
days) (D), or flavopiridol and MPTP (14 days) (E). (F) Quantitation of  FosB-
positive cells; each bar represents mean  SEM; * indicates statistical signifi-
cance (P  0.05, ANOVA, n  6 animals per group).
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icantly attenuated by flavopiridol treatment (Fig. 4 C–F). These
results suggest that cdk inhibition provides functional adaptation
of the basal ganglion (BG) circuitry through inhibition of
postsynaptic changes in the denervated striatum.
Discussion
CDKs and Dopaminergic Neuron Death. Although abnormal levels
activities of both cell cycle-related CDKs and cdk5 have been
implicated in a variety of neurodegenerative conditions, the
fundamental questions of functional importance as well as
identity of individual CDK members required for neuronal death
is unclear. Our present results clarify some of these important
issues. First, we demonstrate that CDK family members play a
required role in nigral degeneration. Second, of the CDK
members examined, cdk5 plays the major role in MPTP-induced
dopaminergic loss. This conclusion is supported by our obser-
vations that cdk5 levels and activity are increased after MPTP
treatment and that DN cdk5 expression inhibits death. This
observation also indicates the requirement of cdk5 as a major
signal in neuronal death pathways in vivo. Third, select cell
cycle-related CDK members such as cdk2 may also play a minor
role in the neurodegenerative process initiated by MPTP. Fi-
nally, the cyclin D1cdk46Rb pathway does not play a role in
MPTP-induced death. In support of this conclusion, expression
of DN cdk4 or DN cdk6 did not prevent dopaminergic loss and
Rb phosphorylation could not be detected after MPTP treat-
ment. The latter observation is particularly intriguing, consid-
ering observations that the cyclin D1, cdk4, and cdk6 activities
have been shown to be required in in vitro models of neuronal
loss (6, 8) and up-regulated in a variety of in vivo contexts,
including ischemia (9, 10). Why cdk2 (at least in a minor fashion)
and not cdk46 and Rb appear to be involved in MPTP-induced
neuronal loss is unclear. However, cdk2 has roles that diverge
from those of cdk46 (47). For example, cdk2 is known to
regulate p53 (48), a required signal for MPTP-induced neuronal
loss (49). It is important to emphasize that our understanding
of the relative contributions of the CDK members is specific to
the present degenerative paradigm, and CDK involvement in
other neuropathological conditions will have to be determined
empirically.
The manner by which cdk5 is activated after MPTP treatment
remains to be fully clarified, but it may include multiple mech-
anisms. An increase in cdk5 levels, as we have shown, may
contribute to the death activation process, whereas posttransla-
tional modifications of cdk5 may be an alternative mechanism to
control activation. In fact, stimulatory phosphorylation of cdk5
on Tyr-15 by c-Abl has been previously reported (50). Finally,
conversion of the cdk5 activator p35 to a more stable p25 form
may lead to increased cdk5 activity. Consistent with this possi-
bility, we have shown an increase in p25 levels after MPTP
treatment. This latter possibility is particularly intriguing. Sev-
eral reports suggest that the p35-to-p25 conversion is mediated
through calpains (23, 51). Interestingly, we have previously
demonstrated that calpains are activated and required for death
in the chronic MPTP paradigm of PD and that calpain activation
also occurs in postmortem PD brains (33).
Although our results validate a role for cdk5 in PD, the precise
mechanism(s) by which cdk5 modulates downstream effectors
remains to be elucidated. Cdk5 may modify cytoskeletal struc-
tures as has been proposed for Alzheimer’s disease (18, 23).
These cytoskeletal abnormalities could lead to activation of
downstream death effectors such as Bax (32) and caspases (52),
which have been implicated in MPTP-induced nigral loss. In
addition, cdk5 may more directly activate other death-related
proteins. In particular, cdk5 is reported to activate p53 (53).
However, cdk5 may also inhibit prosurvival signals. In this
regard, a recent report has indicated that nuclear cdk5 activity
leads to phosphorylation and inactivation of MEF2, a transcrip-
tion factor thought to be required for neuronal survival under
select conditions (54).
A final intriguing possibility is that cdk5 may affect function
of cell cycle-related CDKs. Indeed, the functional role of cell
cycle-related cdks is supported by our present results indicat-
ing protection with DN cdk2 expression. Consistent with the
results presented here, cyclin E, one activator of cdk2, has
recently been shown to be up-regulated in response to a
deficiency of parkin, which is encoded by a gene linked to
familial PD (55). In addition, cdc2 (a cell cycle CDK) expres-
sion has been reported in a neonatal model of induced
dopaminergic neuron loss (31). Although the exact relation-
ship between cell cycle-related CDKs and cdk5 is presently
unknown, cell cycle CDK up-regulation in an amyotrophic
lateral sclerosis (ALS) model is alleviated by expression of
neurofilament H, a proposed phosphorylation sink for cdk5
(56). A similar relationship might exist with PD.
Taking these findings together, an attractive model of
dopaminergic death is one in which cdk5 acts concertedly on
multiple substrates, including cytoskeletal components and
death-related signaling components such as p53, MEF2, and
cell cycle CDKs. These signals act coordinately to regulate a
Bax-mediated death process. The potential convergent actions
of cdk5 may also explain why inhibition of cdk5 is more
effective at neuroprotection than cdk2. However, it will be
important in future experiments to definitively elucidate any
potential downstream target(s) of cdk5 as it relates to dopa-
minergic cell loss.
CDK5 and Striatal Function. An important aspect of our study
critical to development of treatment strategies for PD is the
observation that cdk5 inhibition leads to nigral protection,
normalized markers of BG circuitry, and improved aspects of
behavior. These improvements were not associated with pres-
ervation of striatal dopamine levels or by compensatory in-
creases in dopamine turnover. These observations are consistent
with increasing evidence that the response of the BG to striatal
denervation is not solely dependent upon the loss of striatal
dopamine and that preservation of nigral function may also be
of critical importance. In this regard, it is important to note that
nigral dopaminergic neurons release dopamine not only from
their axons projecting to the striatum but also from their
dendrites (57, 58). This dendrodendritic release of dopamine by
SNc neurons may modulate the BG and explain the behavioral
improvements observed presently (33, 59). Alternatively, CDK
inhibition may directly affect BG neurotransmitter systems at
either postsynaptic striatal sites or other basal ganglia nuclei. In
support of this possibility, cdk5 is reported to play a role in
synaptic transport and dopamine signaling (60). It may therefore
be possible that modulation of cdk5 activity, independent of its
role in nigral death, may affect BG function.
In conclusion, our results represent an important demonstra-
tion that inhibition of CDKs, in a model of PD, not only retards
neurodegeneration but also ameliorates dopamine-related func-
tional impairment in mice. While caution must be exercised in
directly relating the MPTP animal model to the human condi-
tion, we propose that these findings hold potential for the
development of novel PD therapeutic strategies.
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